How to Embed AI into Drug Launch
Drug launch is a critical and complex component in the parma value chain. Now more than ever, pharmaceutical companies face significant challenges. The global pandemic fundamentally transformed how we interact across all levels of society, while rapid technological advances and innovative business models continue to reshape markets. Meanwhile, stakeholder attitudes and expectations are evolving at an unprecedented pace, driven by shifting priorities around sustainability, social responsibility, and digital-first experiences.
Artificial intelligence (AI) is the most appropriate way to meet these new challenges. Implemented properly, AI can be used to bolster sales and marketing efforts, ensure and facilitate market access, streamline regulatory compliance, and boost patient and practitioner engagement and education.
In this article, I look at each of these four key launch areas in detail and provide some keys to leveraging AI for drug launch success.
Sales and Marketing
In pharmaceuticals and beyond, sales and marketing remains one of the domains most transformed by digital innovation. However, according to recent studies, remote sales representative interactions continue to face effectiveness challenges compared to in-person meetings, despite significant improvements in virtual engagement tools and techniques.
Of course, digital sales and marketing tactics and tools, as we’ll see, go far beyond remote meetings—but the data does serve to highlight the fact that prescribing rates have been fundamentally impacted by the shift towards digital solutions, and that there is plenty of room for improvement.
AI can help with this task in a number of ways. First, it can be used with great success in market segmentation, which has overall been quite slow to change despite the many new actors involved (such as pharmacists, physicians’ assistants, and patient associations). Customers today expect a more personalized experience, which requires more granular and data-driven market segmentation. This can only be achieved by compiling and analyzing vast amounts of data from a variety of traditional (e.g., prescribing levels) and novel (e.g., CRM, publications, physician forums, social media behavior) sources—the kind of thing AI excels at.
The same data can be used further down the sales and marketing pipeline as well. Message optimization can be achieved on a large scale thanks to AI and machine learning (ML). This means more relevant information, delivered at the right time and using the most effective channels. With intelligent automation driving such interactions, sales and marketing teams can leverage the many benefits of real-time marketing in ways that were never open to pharmaceutical companies before.
These are just some of the ways AI can be successfully used to boost sales and marketing in pharmaceuticals. For those who are interested, I recommend checking out these 16 examples of successful applications of AI in pharma marketing (Part I; Part II; Part III).
Market Access
In a previous article, I discussed the role of AI in market access and pricing and addressed some of the most salient issues that AI can help address, including shifting expectations regarding reimbursement and delivery models. Much has changed in recent years, and the opportunities to successfully leverage AI and improve market access continue to grow.
Faced with significant challenges, including rising pressure regarding pricing and reimbursement, changing expectations from payers, practitioners and patients, and an increasingly fragmented and complex stakeholder ecosystem, pharmaceutical companies looking to improve on market access must put in place an effective AI market access strategy to better manage and predict pricing, accelerate reimbursements, and engage stakeholders. We explore how in this article.
Regulatory Compliance
The digital age has come with new regulatory hurdles, notably with the advent of digital therapeutics (DTx), a wholly novel set of treatments and regulatory requirements. And as the storage, analysis, and exchange of patient data—both clinical and personal—increases, so too do privacy regulations become more strict, more technical.
Fortunately, there are plenty of digital solutions to help out. In fact, AI approaches can reduce regulatory compliance time by 25% and deliver improved resource management—both of which mean better profits for pharma companies.
Pharmacovigilance also represents an important opportunity for improvements from AI. Data sources and formats continue to increase in diversity and volume, while, from case receipt to reporting, processes are becoming more complex. Only with AI can pharma companies hope to fully benefit from the vast sea of data now available, allowing for more accurate insights along with reduced costs.
Practitioner and Patient Engagement
Finally, AI can help pharmaceutical companies engage more effectively with practitioners and patients, both of whom are eager for more convenient, informative, and candid interactions with providers.
In a webinar from PharmaPhorum, panelists highlighted this point regarding, in particular, young, tech-savvy physicians in search of a better work–life balance. But regardless of age or work habits, many still lament the dated methods used by pharmaceutical companies.
“I still have a stack of business cards with information of 20–30 different pharmaceutical and medical device reps,” says panelist Dr. Mehra. “I cannot think of any other industry that would do that—if I order food or call a cab, everything is streamlined and really done through the phone.” Many of the AI tools used in sales and marketing can be brought to bear on this problem, allowing for more personalized, more accessible, and more transparent interactions with physicians. When it comes to launching new drugs, getting practitioners on board is paramount. AI can help pharma companies do this with staggering effectiveness.
The same goes for engaging directly with patients, something that has always been a rather complex affair for pharmaceutical companies. Historically, practitioners have acted as the middle-man, with little to no bidirectional communication seen between providers and patients. AI is changing this, enabling pharma companies to engage with patients through sophisticated chatbots, for example, and improve patient compliance through AI-powered reminders and phone applications built to accompany molecules.
Keys to Success
As we’ve seen, the potential uses of AI in product launch for pharma are myriad. Pharma companies hoping to successfully embed AI into drug launch should ensure the following goals are met.
First, introduce AI into workflows early on. This is true chronologically, of course, as delays of weeks or even days are typically measured in tens of millions in lost revenue, and implementing an effective AI strategy takes time and planning. But it’s also true processually; introducing AI early on in the drug launch lifecycle means compounded benefits downstream, as insights gleaned from market definition and segmentation feed into regulatory submission and review, product marketing strategies, pricing and reimbursement models, right up to Phase IV and beyond.
One of the reasons this is true is that AI thrives on data. As a general rule, the more you have, the better. Unstructured, unexploited data represents a massive opportunity for most pharma companies. Determine where your richest sources of data lie and then build an AI strategy that leverages them effectively.
Finally, ensure internal stakeholders are enthusiastic about and comfortable using novel AI tools. Establishing a narrative and a roadmap, communicating it and championing it, and empowering people to work in new ways with advanced tools are all part of a successful digital transformation.
Conclusion
Drug launch is a complex and lengthy process, often spanning years and costing millions of dollars. This complexity and length, however, make it a prime candidate for leveraging the power of AI. Sales and marketing, market access, regulatory compliance, and HCP and patient engagement will all benefit from the successful implementation of a well-planned, data-driven AI strategy.
P.S. Here are some ways we can help you accelerate your Pharma AI results:
Dr Bates posts regularly about AI in Pharma so if you follow her you will get even more insights.
We have been doing these for leading pharma companies and agencies since 2011 and have perfected a rigorous approach that is strategy-led for real-world impact on both efficiency and revenue growth.
Revolutionize your team’s AI solution vendor choice process and unlock unparalleled efficiency and save millions on poor AI vendor choices that are not meeting your needs! Stop wasting precious time sifting through countless vendors and gain instant access to a curated list of top-tier companies, expertly vetted by leading pharma AI experts.
Every year, we rigorously interview thousands of AI companies that tackle pharma challenges head-on. Our comprehensive evaluations cover whether the solution delivers what is needed, their client results, their AI sophistication, cost-benefit ratio, demos, and more. We provide an exclusive, dynamic database, updated weekly, brimming with the best AI vendors for every business unit and challenge. Plus, our cutting-edge AI technology makes searching it by business unit, challenge, vendors or demo videos and information a breeze.
1. Discover vendors delivering out-of-the-box AI solutions tailored to your needs.
2. Identify the best of the best effortlessly.
3. Anticipate results with confidence.
Transform your AI strategy with our expertly curated vendors that walk the talk, and stay ahead in the fast-paced world of pharma AI!
Get on the wait list to access this today. Click here.
When we analysed the most successful AI in biopharma and their agencies, we found there are very specific strategies that deliver the most consistent results year after year. This assessment is designed to give clarity as to how to achieve a successful outcome from AI.
The first step is to complete this short questionnaire, it will give us the information to assess which process is right for you as a next step.
It’s free and obligation-free, so go ahead and complete it now. Plus receive a free link to our a free AI tools pdf and our 5 day training (30 mins a day) in AI in pharma. Link to assessment here.
We have created an in-depth on-demand training about AI specifically for pharma that translate it into easy understanding of AI and how to apply it in all the different pharma business units — Click here to find out more.
Andrée, the pace of change keeps accelerating. I'm documenting #BusinessInnovation patterns in mid-market firms - the strategic thinking shift is remarkable. How's the innovation culture at Eularis?
I’d like to gently offer a new perspective; Most of the AI platforms today (Insilico included) are fundamentally statistical — generative, correlational, and heavily reliant on training data. But biology isn't probabilistic at its core. It's governed by deterministic physical and informational constraints. And that's where we come in. At Coherion, we use a quantum-executed validation model (no qubits, no simulation) to collapse biological and chemical systems into their most probable outcome, instantly. It's not generative. It's solved. For example, here’s a real quantum validation we ran on a failed kinase inhibitor — ⚡ Binding free energy: -8.71 kcal/mol ⚡ Pose deviation: 0.34 Å ⚡ ADMET pass, no red flags ⚡ Repositioned indication: Acute Myeloid Leukemia (FLT3 mutant) ⚡ Turnaround: 3 minutes. This is a recovered, validated, IND-ready asset — and we can do up to 50/day. The future isn't "AI-assisted guesswork." It’s quantum-deterministic resolution.
Thanks for sharing, Dr. Andrée
Absolutely spot-on Dr. Andrée Bates What resonates most with me is how AI isn’t just a buzzword, it’s becoming foundational to smarter, faster, and more compliant drug development. As someone with a background in clinical trials and quality, I see AI’s impact especially in protocol design, risk-based monitoring, and submission readiness. We’re moving from reactive QC to predictive QA, and that’s a game-changer. When AI is embedded early, particularly before trial launch, it not only boosts operational efficiency but helps ensure the evidence generated is robust, relevant, and regulator-ready. And with the volume of data growing exponentially, we simply can’t rely on manual processes anymore. Di you think we are training our teams, not just our systems, to work intelligently with AI?
Fascinating!!